American Association for Cancer Research
Browse

Figure S1 from Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery

Download (248.11 kB)
journal contribution
posted on 2023-03-31, 01:27 authored by Huang-Chiao Huang, Imran Rizvi, Joyce Liu, Sriram Anbil, Ashish Kalra, Helen Lee, Yan Baglo, Nancy Paz, Douglas Hayden, Steve Pereira, Brian W. Pogue, Jonathan Fitzgerald, Tayyaba Hasan

The effect of combination PDP and nal-IRI on tumour growth inhibition is synergistic in orthotopic MIA PaCa-2 mouse model.

Funding

National Center for Research Resources

NIH

Massachusetts General Hospital Tosteson Fellowship

Howard Hughes Medical Institute

National Institute for Health Research

History

ARTICLE ABSTRACT

Physiologic barriers to drug delivery and selection for drug resistance limit survival outcomes in cancer patients. In this study, we present preclinical evidence that a subtumoricidal photodynamic priming (PDP) strategy can relieve drug delivery barriers in the tumor microenvironment to safely widen the therapeutic window of a nanoformulated cytotoxic drug. In orthotopic xenograft models of pancreatic cancer, combining PDP with nanoliposomal irinotecan (nal-IRI) prevented tumor relapse, reduced metastasis, and increased both progression-free survival and 1-year disease-free survival. PDP enabled these durable improvements by targeting multiple tumor compartments to (i) increase intratumoral drug accumulation by >10-fold, (ii) increase the duration of drug exposure above a critical therapeutic threshold, and (iii) attenuate surges in CD44 and CXCR4 expression, which mediate chemoresistance often observed after multicycle chemotherapy. Overall, our results offer preclinical proof of concept for the effectiveness of PDP to minimize risks of tumor relapse, progression, and drug resistance and to extend patient survival.Significance: A biophysical priming approach overcomes key treatment barriers, significantly reduces metastases, and prolongs survival in orthotopic models of human pancreatic cancer. Cancer Res; 78(2); 558–71. ©2017 AACR.

Usage metrics

    Cancer Research

    Categories

    Keywords

    BiomarkersMetastasis biomarkersDrug MechanismsGastrointestinal CancersPancreatic cancerPreclinical ModelsAnimal models of cancerProgression, Invasion & MetastasisImaging of tumor progression and metastasisRadiation OncologyCombined modality therapiesPhotobiology/photodynamic therapyRadiobiologyRadiation and tumor microenvironmentSmall Molecule AgentsTopoisomerase agentsStem Cell Biology

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC